We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

64 hedge funds and large institutions have $180M invested in CRISPR Therapeutics in 2017 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

833% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 3

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

64% more funds holding

Funds holding: 39 → 64 (+25)

16% more capital invested

Capital invested by funds: $155M → $180M (+$24.5M)

0.68% more ownership

Funds ownership: 24.09% → 24.77% (+0.68%)

97% less call options, than puts

Call options by funds: $27K | Put options by funds: $983K

Holders
64
Holders Change
+25
Holders Change %
+64.1%
% of All Funds
1.6%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.15%
New
28
Increased
14
Reduced
6
Closed
3
Calls
$27K
Puts
$983K
Net Calls
-$956K
Net Calls Change
-$635K

Top Buyers

Rank Fund Capital Flow
1
GTP
Global Thematic Partners
New York
+$10.3M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.75M
3
Allianz Asset Management
Allianz Asset Management
Germany
+$2.42M
4
HP
Harbourvest Partners
Massachusetts
+$1.77M
5
GIM
Granahan Investment Management
Massachusetts
+$1.63M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$12.9M
2
A
Abingworth
United Kingdom
-$8.57M
3
PC
Paulson & Co
New York
-$457K
4
CCP
Clough Capital Partners
Massachusetts
-$314K
5
PCMM
Private Capital Management (Minnesota)
Minnesota
-$80K
Name Holding Trade Value Shares
Change 		Change in
Stake
RE
51
RBC Europe
United Kingdom
$10.7K +$10.9K +600 New
UBS Group
52
UBS Group
Switzerland
$10K -$17.4K -958 -63%
CG
53
Cutler Group
California
$10K +$4.77K +263 +78%
MFW
54
Mosaic Family Wealth
Missouri
$9K – – –
CFA
55
Carroll Financial Associates
North Carolina
$8K – – –
KF
56
Krilogy Financial
Missouri
$5K – – –
FDCDDQ
57
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.47K -$9.97K -550 -69%
CCM
58
Covington Capital Management
California
$4K +$3.63K +200 New
ASN
59
Advisory Services Network
Georgia
$2K – – –
CCM
60
Cribstone Capital Management
Maine
$2K – – –
WIM
61
Westside Investment Management
California
$1.97K – – –
AWM
62
AllSquare Wealth Management
New York
$1K +$1.09K +60 New
VFA
63
Valeo Financial Advisors
Indiana
$1K +$1.27K +70 New
PC
64
Paulson & Co
New York
– -$457K -28,500 Closed
PCMM
65
Private Capital Management (Minnesota)
Minnesota
– -$80K -5,000 Closed
IP
66
Intellectus Partners
California
– -$7K -425 Closed
Citigroup
67
Citigroup
New York
– +$181 +10 New
1 2
3

CRSP Hedge Fund Activity: Q3 2017 in Review

64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2017, worth a combined $180M — up 16% from $155M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CRSP positions and 3 closed out — a net gain of 25 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Global Thematic Partners, opening a new position worth an estimated $10.3M. The largest seller was Morgan Stanley, cutting an estimated $12.9M.

  • 64 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2017, up from 39 in Q2 2017.
  • Funds reported $180M of CRISPR Therapeutics stock for Q3 2017, up 16% quarter-over-quarter.
  • 28 funds opened new CRISPR Therapeutics positions in Q3 2017 and 3 closed out, a net change of +25 holders.
  • The largest CRISPR Therapeutics buyer in Q3 2017 was Global Thematic Partners, an estimated $10.3M added.
  • The largest CRISPR Therapeutics seller in Q3 2017 was Morgan Stanley, an estimated $12.9M sold.

Based on aggregated 13F filings for Q3 2017.